Birt-Hogg-DubeÂ syndrome (BHD) is an autosomal dominant neoplasia syndrome characterized mainly by benign skin tumors, and to a lesser extent, renal tumors and spontaneous pneumothorax. To map the BHD locus, we performed a genome-wide linkage analysis using polymorphic microsatellite markers on a large Swedish BHD family. Evidence of linkage was identi®ed on chromosome 17p12-q11.2, with a maximum LOD score of 3.58 for marker D17S1852. Further haplotype analysis de®ned a *35 cM candidate interval between the two¯anking markers, D17S1791 and D17S798. This information will facilitate the identi®cation of the BHD gene, leading to the understanding of its underlying molecular etiology. Oncogene (2001) 20, 5239 ± 5242.
, characterized by a triad of cutaneous lesions composing multiple ®brofolliculomas, trichodiscomas and acrochordons, was ®rst described by Birt et al. (1977) . The trichodiscomas and ®brofolliculomas typically appear as multiple small, dome-shaped, yellowish or skincolored papules, scattered over the face, neck, scalp and upper trunk. They are tumors of the perifollicular mesenchyme and it is not possible to distinguish them clinically. Fibrofolliculomas consist of abnormal hair follicles with epithelial strands extending from the infundibulum of the hair follicle into a hyperplastic mantle of ®brous tissue. The epithelial strands may anastomose or rejoin the infundibulum at several points. Trichodiscomas are hamartomas of the dermal portion of the hair disc and share the histological features of ®brofolliculomas, but contain predominantly the ®brous component. The third skin lesions, the acrochodons, are less speci®c and reports have shown cases whereby patients with ®brofolliculomas and trichodiscomas did not have acrochodons (Foucar et al., 1981; Starink et al., 1985; Starink and Brownstein, 1987; Moreno et al., 1985) . Moreover, it has been argued that the clinically acrochodon-like lesions in BHD patients indeed are histological variations of the trichodiscoma/®brofolliculoma spectrum and not a separate entity (De la Torre et al., 1999) . BHD is transmitted in an autosomal dominant fashion and the skin lesions are usually shown in the third decade of life. As BHD is a rare neoplasia syndrome, its population frequency and occurrence in sporadic versus familial cases are yet to be established.
A wide spectrum of BHD-related features has been described and listed by Schulz and Hartschuh (1999) . The BHD-related renal tumors, for example, appear to vary in histological features and have been reported as oncocytoma, papillary RCC and clear cell RCC (Roth et al., 1993; Toro et al., 1999) . Lung diseases such as bronchiectasis, bronchospasm (Moreno et al., 1985) and spontaneous pneumothorax (Chung et al., 1996; Toro et al., 1999) have also been associated with BHD patients. In addition, colonic neoplasms (Rongioletti et al., 1989; Haimowitz et al., 1997) , large connective tissue nevus (Weintraub and Pinkus, 1977) , multiple lipomas, angiolipomas and parathyroid adenomas (Chung et al., 1996) have been described.
To date the locus of the BHD gene remains unknown. Here, we performed a genome-wide scan on 17 individuals of a Swedish pedigree (Figure 1 ) to identify the susceptibility locus of BHD. 1999) suggest that the BHD gene may play an important role in the dierentiation process of renal cells. In addition, two cases of breast ®broadenoma-tosis (III : 2 and IV : 2) are found in this family. Fibroadenoma of the breast is very common in the general population and therefore its association with BHD needs to be further explored.
Four hundred¯uorescence-labeled primer pairs from ABI Prism human linkage mapping set version 2 (PE Biosystem) at an average spacing of 10 cM were used. PCR ampli®cations were performed according to the manufacturer's recommended protocols and set up in 96-well polypropylene microplates (MJ Research). PCR ampli®ed products were denatured and size-fractioned on a 4.2% polyacrylamide gel on an ABI 377 sequencer (PE Biosystem). Genotypes were determined using Genescan version 3.1 and Genotyper version 2.5 (PE Biosystem). After preliminary analysis suggested its possible linkage to chromosome 17, additional chromosome 17 markers with 5 cM spacing were obtained from the ABI Prism human linkage mapping set-HD5 (PE Biosystem).
Linkage analysis was performed using two-point LOD score by MLink of the Linkage package (Lathrop et al., 1985; Terwilliger and Ott, 1994) . The disease was modeled as autosomal dominant with complete penetrance. A conservative approach was applied in which age 50 was taken as the cut-o point: healthy individuals above 50 are considered as unaected whereas those below 50 are considered as unknown. For example, individual VI : 1 (Figure 1 ) who is 9 years old, is considered as unknown. Genetic distances between microsatellite markers were obtained from the Center for Medical Genetics, Marsh®eld Medical Research Foundation.
We found a maximum LOD score (Z max ) between the disease locus and microsatellite marker (D17S1852 (Z max =3.58 at recombination fraction [y] 0; Table 2 ). Additional two-point LOD scores were obtained with six other adjacent markers.
Haplotype analysis (Figure 1) showed a recombination event between markers D17S1791 and D17S1852 in individual III : 2, IV : 2, IV : 4, IV : 10, V : 1, V : 3, and V : 4, as well as between D17S1824 and D17S798 in individual IV : 10. Therefore the disease gene in this BHD family lies within a 35.5 cM region on chromosome 17p12-q11.2.
More than 100 known genes and anonymous ESTs have been assigned to this interval and some of these are interesting candidates for BHD. (Hemminki et al., 1998; Jenne et al., 1998) .
A good way to shorten the list of potential candidates will be to know if the BHD gene is a tumor suppressor gene based on loss of heterozygosity (LOH) studies, which will involve the loss of the wild-type alleles in the BHD tumors. Therefore, we are currently collecting the BHD tumors in this family for investigating their LOH status. In addition, more BHD families will be collected to establish its genetic homogeneity as well as to detect additional recombinations that may further narrow the mapped region.
In conclusion, we have mapped a candidate locus associated with BHD on chromosome 17p12-q11.2. This information can be used to identify individuals at risk in BHD families. It will also facilitate the identi®cation of the BHD gene, which will enhance our understanding of the pathogenesis of BHD and its wide spectrum of tumors.
